Skip to main content
SpringerLink
Log in

Respiratory System Involvement in Antineutrophil Cytoplasmic-Associated Systemic Vasculitides

Clinical, Pathological, Radiological and Therapeutic Considerations

  • Review Article
  • Published:
Drugs in R & D Aims and scope Submit manuscript

Abstract

Wegener’s granulomatosis (WG), microscopic polyangiitis (MPA) and Churg-Strauss syndrome (CSS) are small-vessel vasculitides that, because of their frequent association with antineutrophil cytoplasmic antibodies (ANCA), are usually referred to as ANCA-associated systemic vasculitides (AASV). The diagnosis of AASV is made on the basis of clinical findings, biopsy of an involved organ and the presence of ANCA in the serum. Lung disease is a very common and important clinical feature of AASV. In WG, almost all patients have either upper airway or lower respiratory tract disease. Solitary or multiple nodules, frequently cavitated, and masses are the most common findings on chest radiography. Asthma is a cardinal symptom of CSS, often preceded by allergic rhinitis. Pulmonary transient and patchy alveolar infiltrates are the most common radiographic findings. In MPA, diffuse alveolar haemorrhage as a result of alveolar capillaritis is the most frequent manifestation of respiratory involvement, and is clinically expressed as haemoptysis, respiratory distress and anaemia. However, diffuse alveolar haemorrhage may also be subclinical and should be suspected when a chest radiograph demonstrates new unexplained bilateral alveolar infiltrates in the context of falling haemoglobin levels. Normal and high-resolution CT have a higher sensitivity than chest radiography for demonstrating airway, parenchymal and pleural lesions. However, many of these radiological findings are nonspecific and, therefore, their interpretation must take into account all clinical, laboratory and pathological data. Therapy of AASV is commonly divided into two phases: an initial ‘remission induction’ phase, in which more intensive immunosuppressant therapy is used to control disease activity, and a ‘maintenance’ phase, which uses less intensive therapy, for maintaining disease remission while lowering the risk of adverse effects of immunosuppressant drugs. In patients with AASV refractory to standard therapy with corticosteroids and oral cyclophosphamide, new therapeutic options are now available. Recurrence of pulmonary symptoms suggesting a flare indicates the need for a careful search for an opportunistic lung infection or iatrogenic pulmonary complications.

In conclusion, involvement of the respiratory system is a very common and important organ manifestation of AASV. Respiratory system involvement comprises a wide spectrum of clinical features and radiological findings, and because of its frequency and prognostic significance, a complete assessment of the respiratory system should be included in the work-up of all patients with AASV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Fauci AS, Haynes BF, Katz P. The spectrum of vasculitis: clinical, pathologic, immunologic, and therapeutic considerations. Ann Intern Med 1978; 89: 660–76

    PubMed  CAS  Google Scholar 

  2. Gross WL. Immunopathogenesis of vasculitis. In: Klippel JH, Dieppe PA, editors. Rheumatology. 2nd ed. London: Mosby, 1998: 7.19.1–19.8.3

    Google Scholar 

  3. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997; 337: 1512–23

    Article  PubMed  CAS  Google Scholar 

  4. Manganelli P, Fietta P, Carotti M, et al. Respiratory system involvement in the systemic vasculitides. Clin Exp Rheum 2006; 24 Suppl. 41: S48–59

    CAS  Google Scholar 

  5. Pavone L, Grasselli C, Chierici E, et al. Outcome and prognostic factors during the course of primary small-vessel vasculitides. J Rheumatol 2006; 33: 1299–306

    PubMed  Google Scholar 

  6. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener’s granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488–98

    PubMed  CAS  Google Scholar 

  7. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021–32

    Article  PubMed  CAS  Google Scholar 

  8. Stone JH. Wegener’s Granulomatosis Etanercept Trial Research Group. Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s Granulomatosis Etanercept Trial. Arthritis Rheum 2003; 48: 2299–309

    Article  PubMed  Google Scholar 

  9. Langford CA, Sneller MC, Hallahan CW, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosis. Arthritis Rheum 1996; 39: 1754–60

    Article  PubMed  CAS  Google Scholar 

  10. Daum TE, Specks U, Colby TV, et al. Tracheobronchial involvement in Wegener’s granulomatosis. Am J Respir Crit Care Med 1995; 151: 522–6

    PubMed  CAS  Google Scholar 

  11. Belostotsky VM, Shah V, Dillon M. Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatr Nephrol 2002; 17: 754–61

    Article  PubMed  Google Scholar 

  12. Rottem M, Fauci AS, Hallahan CW, et al. Wegener’s granulomatosis in children and adolescent: clinical presentation and outcome. J Pediatr 1993; 122: 26–31

    Article  PubMed  CAS  Google Scholar 

  13. Schwarz MI, Brown KK. Small vessel vasculitis of the lung. Thorax 2000; 55: 502–10

    Article  PubMed  CAS  Google Scholar 

  14. Bosch X, López-Soto A, Mirapeix E, et al. Antineutrophil cytoplasmic autoantibody-associated alveolar capillaritis in patients presenting with pulmonary haemorrhage. Arch Pathol Lab Med 1994; 118: 517–22

    PubMed  CAS  Google Scholar 

  15. ter Maaten JC, Franssen CFM, Gans ROB, et al. Respiratory failure in ANCA-associated vasculitis. Chest 1996; 110: 357–62

    Article  PubMed  Google Scholar 

  16. Green RJ, Ruoss SJ, Kraft SA, et al. Pulmonary capillaritis and alveolar hemorrhage: update on diagnosis and management. Chest 1996; 110: 1305–16

    Article  PubMed  CAS  Google Scholar 

  17. Louthrenoo W, Norasetthada A, Khunamornpong S, et al. Childhood Churg-Strauss syndrome. J Rheumatol 1999; 26: 1387–93

    PubMed  CAS  Google Scholar 

  18. Boyer D, Vargas SO, Slattery D, et al. Churg-Strauss syndrome in children: a clinical and pathologic review. Pediatrics 2006; 118: 914–20

    Article  Google Scholar 

  19. Lanham JC, Elkon KB, Pusey CD, et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine 1984; 63: 65–81

    Article  PubMed  CAS  Google Scholar 

  20. Abril A, Calamia KT, Cohen MD. The Churg-Strauss syndrome (allergic granulomatous angiitis): review and update. Semin Arthritis Rheum 2003; 33: 106–14

    Article  PubMed  Google Scholar 

  21. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine 1999; 78: 26–37

    Article  PubMed  CAS  Google Scholar 

  22. Yamashita Y, Yorioka N, Taniguchi Y, et al. Nonasthmatic case of Churg-Strauss syndrome with rapidly progressive glomerulonephritis. Intern Med 1998; 37: 561–3

    Article  PubMed  CAS  Google Scholar 

  23. Malik TQ, Youmbissi TJ, Gacha R, et al. Atypical presentation of Churg-Strauss syndrome: another “forme fruste” of the disease? Am J Med Sci 2002; 324: 276–8

    Article  PubMed  CAS  Google Scholar 

  24. Sevinc A, Hasanouglu HC, Gokirmak M, et al. Allergic granulomatosis and angiitis in the absence of asthma and blood eosinophilia: a rare presentation of limited Churg-Strauss syndrome. Rheumatol Int 2004; 24: 301–4

    Article  PubMed  Google Scholar 

  25. Clutterbuck EJ, Pusey CD. Severe alveolar haemorrhage in Churg-Strauss syndrome. Eur J Respir Dis 1987; 71: 158–63

    PubMed  CAS  Google Scholar 

  26. Lai R-S, Lin S-L, Lai N-S, et al. Churg-Strauss syndrome presenting with pulmonary capillaritis and diffuse alveolar hemorrhage. Scand J Rheumatol 1998; 27: 230–2

    Article  PubMed  CAS  Google Scholar 

  27. Solans R, Bosch JA, Pérez-Bocanegra C, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology 2001; 40: 763–71

    Article  PubMed  CAS  Google Scholar 

  28. Della Rossa A, Baldini C, Tavoni A, et al. Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre. Rheumatology 2002; 41: 1286–94

    Article  PubMed  Google Scholar 

  29. Erzurum SC, Underwood GA, Hamilos DL, et al. Pleural effusion in Churg-Strauss syndrome. Chest 1989; 95: 1357–9

    Article  PubMed  CAS  Google Scholar 

  30. Guillevin L, Durant-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42: 421–30

    Article  PubMed  CAS  Google Scholar 

  31. Peco-Antic A, Bonaci-Nikolic B, Basta-Jovanovic G, et al. Childhood microscopic polyangiitis associated with myeloperoxidase-ANCA. Pediatr Nephrol 2006; 21: 46–53

    Article  PubMed  Google Scholar 

  32. Lauque D, Cadranel J, Lazor R, et al. Microscopic polyangiitis with alveolar haemorrhage: a study of 29 cases and review of the literature. Medicine 2000; 79: 222–33

    Article  PubMed  CAS  Google Scholar 

  33. Schwarz MI, Mortenson RL, Colby TV, et al. Pulmonary capillaritis: the association with progressive irreversible airflow limitation and hyperinflation. Am Rev Respir Dis 1993; 148: 507–11

    PubMed  CAS  Google Scholar 

  34. Brugiere O, Raffy O, Sleiman C, et al. Progressive obstructive lung disease associated with microscopic polyangiitis. Am J Respir Crit Care Med 1997; 155: 739–42

    PubMed  CAS  Google Scholar 

  35. Becker-Merok A, Nessent JC, Ritland N. Fibrosing alveolitis predating microscopic polyangiitis. Scand J Rheumatol 1999; 28: 254–6

    Article  PubMed  CAS  Google Scholar 

  36. Eschun GM, Mink SN, Sharma S. Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis. Chest 2003; 123: 297–301

    Article  PubMed  Google Scholar 

  37. Watz H, Hammerl P, Matter C, et al. Bronchioloalveolar carcinoma of the lung associated with a highly positive pANCA-titer and clinical signs of microscopic polyangiitis [in German]. Pneumologie 2004; 58: 493–8

    Article  PubMed  CAS  Google Scholar 

  38. Bosch X, Font J. The pulmonary-renal syndrome: a poorly understood clinicopathologic condition. Lupus 1999; 8: 258–62

    Article  PubMed  CAS  Google Scholar 

  39. Radice A, Sinico RA. Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity 2005; 38: 93–103

    Article  PubMed  CAS  Google Scholar 

  40. Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53: 743–53

    Article  PubMed  CAS  Google Scholar 

  41. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52: 2926–35

    Article  PubMed  CAS  Google Scholar 

  42. Sablè-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg Strauss-syndrome. Ann Intern Med 2005; 143: 632–8

    PubMed  Google Scholar 

  43. Russell KA, Wiegert E, Schroeder DR, et al. Detection of antineutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol 2002; 103: 196–203

    Article  PubMed  CAS  Google Scholar 

  44. Vassilopoulos D, Niles JL, Villa-Forte A, et al. Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multiorgan dysfunction. Arthritis Rheum 2003; 49: 151–5

    Article  PubMed  Google Scholar 

  45. Birck R, Schmitt WH, Kaelsch IA, et al. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis 2006; 47: 15–23

    Article  PubMed  Google Scholar 

  46. Schmitt WH, Csernok E, Kobayashi S, et al. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum 1998; 41: 445–52

    Article  PubMed  CAS  Google Scholar 

  47. Gross WL. Churg-Strauss syndrome: update on recent development. Curr Opin Rheumatol 2002; 14: 11–4

    Article  PubMed  CAS  Google Scholar 

  48. Eberhard OK, Haubitz M, Brunkhorst FM, et al. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 1997; 40: 1250–6

    PubMed  CAS  Google Scholar 

  49. Rosenberg DM, Weinberger SE, Fulmer JD, et al. Functional correlates of lung involvement in Wegener’s granulomatosis: use of pulmonary function tests in staging and follow-up. Am J Med 1980; 69: 387–94

    Article  PubMed  CAS  Google Scholar 

  50. Newall C, Schinke S, Savage CO, et al. Impairment of lung function, health status and functional capacity in patients with ANCA-associated vasculitis. Rheumatology 2005; 44: 623–8

    Article  PubMed  CAS  Google Scholar 

  51. Cordier JF, Valeyre D, Guillevin L, et al. Pulmonary Wegener’s granulomatosis: a clinical and imaging study of 77 cases. Chest 1990; 97: 906–12

    Article  PubMed  CAS  Google Scholar 

  52. Papiris SA, Manoussakis MN, Drosos AA, et al. Imaging of thoracic Wegener’s granulomatosis: the computed tomographic appearance. Am J Med 1992; 93: 529–36

    Article  PubMed  CAS  Google Scholar 

  53. Seo JB, Im JG, Chung JW, et al. Pulmonary vasculitis: the spectrum of radiological findings. Br J Radiol 2000; 73: 1224–31

    PubMed  CAS  Google Scholar 

  54. Rockall AG, Rickards D, Shaw PJ. Imaging of the pulmonary manifestations of systemic disease. Postgrad Med J 2001; 77: 621–38

    Article  PubMed  CAS  Google Scholar 

  55. Aberle DR, Gamsu G, Lynch D. Thoracic manifestations of Wegener’s granulomatosis: diagnosis and course. Radiology 1990; 174: 703–9

    PubMed  CAS  Google Scholar 

  56. Kuhlman JE, Hruban RH, Fishman EK. Wegener’s granulomatosis: CT features of parenchymal lung disease. J Comput Assist Tomogr 1991; 15: 948–52

    Article  PubMed  CAS  Google Scholar 

  57. Lee SK, Kim TS, Fujimoto K, et al. Thoracic manifestations of Wegener’s granulomatosis: CT findings in 30 patients. Eur Radiol 2003; 13: 43–51

    Article  PubMed  Google Scholar 

  58. Komócsi A, Reuter M, Heller M, et al. Active disease and residual damage in treated Wegener’s granulomatosis: an observational study using pulmonary high resolution computed tomography. Eur Radiol 2003; 13: 36–42

    PubMed  Google Scholar 

  59. Primack SL, Hartman TE, Lee KS, et al. Pulmonary nodules and the CT halo sign. Radiology 1994; 190: 513–5

    PubMed  CAS  Google Scholar 

  60. Haas C, Geneau C, Odinot JM, et al. Allergic angiitis and granulomatosis: Churg-Strauss syndrome. Retrospective study of 16 cases. Ann Med Interne 1991; 142: 335–42

    CAS  Google Scholar 

  61. Silva CI, Muller NL, Fujimoto K, et al. Churg-Strauss syndrome: high resolution CT and pathologic findings. J Thorac Imaging 2005; 20: 74–80

    Article  PubMed  Google Scholar 

  62. Collins CE, Quismorio FP. Pulmonary involvement in microscopic polyangiitis. Curr Opin Pulm Med 2005; 11: 447–51

    Article  PubMed  Google Scholar 

  63. Schnabel A, Holl-Ulrich K, Dalhoff K, et al. Efficacy of transbronchial biopsy in pulmonary vasculitides. Eur Respir J 1997; 10: 2738–43

    Article  PubMed  CAS  Google Scholar 

  64. Hoffman GS, Sechler JMG, Gallin JI, et al. Bronchoalveolar lavage analysis in Wegener’s granulomatosis: a method to study disease pathogenesis. Am Rev Respir Dis 1991; 143: 401–7

    PubMed  CAS  Google Scholar 

  65. Schnabel A, Csernok E, Gross WL. Activation of neutrophils, eosinophils, and lymphocytes in the lower respiratory tract in Wegener’s granulomatosis. Am J Respir Crit Care Med 2000; 161: 399–40

    PubMed  CAS  Google Scholar 

  66. Schnabel A, Reuter M, Gloeckner K, et al. Bronchoalveolar lavage cell profile in Wegener’s granulomatosis. Respir Med 1999; 93: 498–506

    Article  PubMed  CAS  Google Scholar 

  67. Csernok E, Trabandt A, Muller A, et al. Cytokine profile in Wegener’s granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 1999; 42: 742–50

    Article  PubMed  CAS  Google Scholar 

  68. Olivieri D, Pesci A, Bertorelli G. Eosinophilic alveolitis in immunologic interstitial lung disorders. Lung 1990; 168 Suppl.: 964–73

    Article  PubMed  Google Scholar 

  69. Wallaert B, Gosset P, Prin L, et al. Bronchoalveolar lavage in allergic granulomatosis and angiitis. Eur Respir J 1993; 6: 413–7

    PubMed  CAS  Google Scholar 

  70. Schnabel A, Csernok E, Braun J, et al. Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome. Thorax 1999; 54: 771–8

    Article  PubMed  CAS  Google Scholar 

  71. Manganelli P, Giacosa R, Fietta P, et al. Familial vasculitides: Churg-Strauss syndrome and Wegener’s granulomatosis in two first-degree relatives. J Rheumatol 2003; 30: 618–21

    PubMed  Google Scholar 

  72. Travis WD, Hoffman GS, Leavitt RY, et al. Surgical pathology of the lung in Wegener’s granulomatosis: review of 87 open lung biopsies from 67 patients. Am J Surg Pathol 1991; 19: 315–33

    Article  Google Scholar 

  73. Gaudin PB, Askin FB, Falk RJ, et al. The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and antimyeloperoxidase. Am J Clin Pathol 1995; 104: 7–16

    PubMed  CAS  Google Scholar 

  74. Devankey KO, Travis WD, Hoffman G, et al. Interpretation of head and neck biopsies in Wegener’s granulomatosis: a pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 1990; 14: 555–64

    Article  Google Scholar 

  75. Katzenstein AL. Diagnostic features and differential diagnosis of Churg-Strauss syndrome in the lung: a review. Am J Clin Pathol 2000; 114: 767–72

    Article  PubMed  CAS  Google Scholar 

  76. Bacciu A, Bacciu S, Mercante G, et al. Ear-nose and throat manifestations of Churg-Strauss syndrome. Acta Otolaryngol 2006; 126: 503–9

    Article  PubMed  Google Scholar 

  77. Rasmussen N, Abramowicz D, Andrassy K, et al. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. Clin Exp Immunol 1995; 101 Suppl. 1: 29–34

    Google Scholar 

  78. Jayne DRW, Rasmussen N, for the European Community Systemic Vasculitis Clinical Trials Study Group (ECSYSVASTRIAL). Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trial Study Group. Mayo Clin Proc 1997; 72: 737–47

    Article  PubMed  CAS  Google Scholar 

  79. DeRemee RA, McDonald TJ, Weiland LH. Wegener’s granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc 1985; 60: 27–32

    Article  PubMed  CAS  Google Scholar 

  80. Hoffman GS, Leavitt RY, Kerr GS, et al. The treatment of Wegener’s granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992; 35: 1322–9

    PubMed  CAS  Google Scholar 

  81. Sneller MC, Hoffman GS, Talar-Williams C, et al. An analysis of forty-two Wegener’s granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 608–13

    Article  PubMed  CAS  Google Scholar 

  82. de Groot K, Muhler M, Reinhold-Keller E, et al. Induction of remission in Wegener’s granulomatosis with low dose methotrexate. J Rheumatol 1998; 25: 492–5

    PubMed  Google Scholar 

  83. Stone JH, Tun W, Hellman DB. Treatment of non-life threatening Wegener’s granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 1999; 26: 1134–9

    PubMed  CAS  Google Scholar 

  84. Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener’s granulomatosis: long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000; 43: 1836–40

    Article  PubMed  CAS  Google Scholar 

  85. Metzler C, Hellmich B, Gause A, et al. Churg-Strauss syndrome: successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004; 22 Suppl. 36: S52–61

    PubMed  CAS  Google Scholar 

  86. Fauci AS, Katz P, Haynes BF, et al. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979; 301: 235–8

    Article  PubMed  CAS  Google Scholar 

  87. de Groot K, Adu D, Savage C. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001; 16: 2018–27

    Article  PubMed  Google Scholar 

  88. Reinhold-Keller E, Kekow J, Schnabel A, et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener’s granulomatosis. Arthritis Rheum 1994; 37: 919–24

    Article  PubMed  CAS  Google Scholar 

  89. Lê Thu Huong D, Papo T, Piette JC, et al. Monthly intravenous pulse cyclophosphamide therapy in Wegener’s granulomatosis. Clin Exp Rheumatol 1996; 14: 9–16

    Google Scholar 

  90. Pusey CD, Rees AJ, Evans DJ, et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991; 40: 757–63

    Article  PubMed  CAS  Google Scholar 

  91. Guillevin L, Lhote F, Cohen P, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis: a prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995; 38: 1638–45

    Article  PubMed  CAS  Google Scholar 

  92. Gaskin G, Pusey C. Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Ther Apher 2001; 5: 176–81

    Article  PubMed  CAS  Google Scholar 

  93. Frasca GM, Soverini ML, Falaschini A, et al. Plasma exchange treatment improves prognosis of antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis: a case-con-trol study in 26 patients from a single center. Ther Apher Dial 2003; 7: 540–6

    Article  PubMed  Google Scholar 

  94. Jayne DRW, Esnault VLM, Lockwood CM. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun 1993; 6: 207–19

    Article  PubMed  CAS  Google Scholar 

  95. Jayne DRW, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 2000; 93: 433–9

    Article  CAS  Google Scholar 

  96. Kamesh L, Harper L, Savage CO. ANCA-positive vasculitis. J Am Soc Nephrol 2002; 13: 1953–60

    Article  PubMed  Google Scholar 

  97. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-a blockade with infliximab in refractory Wegener’s granulomatosis. Rheumatology 2002; 41: 1303–7

    Article  PubMed  CAS  Google Scholar 

  98. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti- TNF alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 2002; 41: 1126–32

    Article  PubMed  CAS  Google Scholar 

  99. Arbach O, Gross WL, Gause A. Treatment of refractory Churg- Strauss-Syndrome (CSS) by TNF alpha blockade. Immunobiology 2002; 206: 496–501

    Article  PubMed  CAS  Google Scholar 

  100. Booth AD, Jefferson HJ, Ayliffe W, et al. Safety and efficacy of TNFα blockade in relapsing vasculitis [abstract]. Ann Rheum Dis 2002; 61: 559

    Article  PubMed  CAS  Google Scholar 

  101. Booth A, Harper L, Hammad T, et al. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody associated systemic vasculitis. J Am Soc Nephrol 2004; 15: 717–21

    Article  PubMed  CAS  Google Scholar 

  102. Stone JH, Uhlfelder ML, Hellmann DB, et al. Etanercept combined with conventional treatment in Wegener’s granulo-matosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001; 44: 1149–54

    Article  PubMed  CAS  Google Scholar 

  103. The Wegener’s Granulomatosis Etanercept Trial (WEGT) Research Group. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 2005; 352: 351–61

    Article  Google Scholar 

  104. Lúdvísson B, Sneller MC, Chua KS, et al. Active Wegener’s granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 1998; 160: 3602–9

    Google Scholar 

  105. Komocsi A, Lamprecht P, Csernok E, et al. Peripheral blood and granuloma CD4+ CD28- T cells are a major source of interferon-γ and tumor necrosis factor-α in Wegener’s granulo-matosis. Am J Pathol 2002; 160: 1717–24

    Article  PubMed  CAS  Google Scholar 

  106. Mestre M, Bas J, Alsina J, et al. Depleting effects of antithymocyte globulin on T-lymphocyte subsets in kidney transplantation. Transplant Proc 1999; 31: 2254–5

    Article  PubMed  CAS  Google Scholar 

  107. Schmitt WH, Hagen EC, Neumann I, et al. Treatment of refractory Wegener’s granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004; 65: 1440–8

    Article  PubMed  CAS  Google Scholar 

  108. Voswinkel J, Mueller A, Kraemer JA, et al. B lymphocyte maturation in Wegener’s granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 2006; 65: 859–64

    Article  PubMed  CAS  Google Scholar 

  109. Specks U, Fervenza FC, McDonald TJ, et al. Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001; 44: 2836–40

    Article  PubMed  CAS  Google Scholar 

  110. Keogh K, Wylam M, Stone J, et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 262–8

    Article  PubMed  Google Scholar 

  111. Keogh K, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173: 180–7

    Article  PubMed  CAS  Google Scholar 

  112. Arie PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65: 853–8

    Article  CAS  Google Scholar 

  113. Flossmann O, Jones RB, Jayne DRW, et al. Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? Ann Rheum Dis 2006; 65: 841–4

    Article  PubMed  CAS  Google Scholar 

  114. Schmitt WH, Birck R, Heinzel PA, et al. Prolonged treatment of refractory Wegener’s granulomatosis with 15-deoxys-pergualin: an open study in seven patients. Nephrol Dial Transplant 2005; 20: 1083–92

    Article  PubMed  CAS  Google Scholar 

  115. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998; 129: 370–4

    PubMed  CAS  Google Scholar 

  116. Simon HU, Seelbach H, Ehmann R, et al. Clinical and immuno- logical effects of low-dose IFN-alpha treatment in patients with corticosteroid-resistant asthma. Allergy 2003; 58: 1250–5

    Article  PubMed  CAS  Google Scholar 

  117. Fauci AS, Haynes BF, Katz P, et al. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76–85

    PubMed  CAS  Google Scholar 

  118. Gordon M, Luqmani RA, Adu D, et al. Relapse in patients with systemic vasculitis. Q J Med 1993; 86: 779–89

    PubMed  CAS  Google Scholar 

  119. Bradley JD, Brandt KD, Katz BP. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989; 32: 45–53

    Article  PubMed  CAS  Google Scholar 

  120. Knight A, Askling J, Granath F, et al. Urinary bladder cancer in Wegener’s granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 2004; 63: 1307–11

    Article  PubMed  CAS  Google Scholar 

  121. Klemmer PJ, Chalermskulrat W, Reif MS, et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small vessel vasculitis. Am J Kidney Dis 2003; 42: 1149–53

    Article  PubMed  Google Scholar 

  122. Jayne D, Rasmussen N, Andrasy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineu-trophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36–44

    Article  PubMed  CAS  Google Scholar 

  123. Slot MC, Tervaert JW, Boomsma MM, et al. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004; 51: 269–73

    Article  PubMed  CAS  Google Scholar 

  124. Reinhold-Keller E, Fink C, Herlyn K, et al. High rate of renal relapse in 71 patients with Wegener’s granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002; 47: 326–32

    Article  PubMed  CAS  Google Scholar 

  125. Langford CA, Talar-Williams C, Barron KS, et al. A staged approach to the treatment of Wegener’s granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42: 2666–73

    Article  PubMed  CAS  Google Scholar 

  126. Langford CA, Talar-Williams C, Barron KS, et al. Use of cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener’s granulomatosis: extended follow-up and rate of relapse. Am J Med 2003; 114: 463–9

    Article  PubMed  CAS  Google Scholar 

  127. de Groot K, Rasmussen N, Bacon PA. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 2461–9

    Article  PubMed  CAS  Google Scholar 

  128. Chong AS, Rezai K, Gebel HM, et al. Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro. Transplantation 1996; 61: 140–5

    Article  PubMed  CAS  Google Scholar 

  129. Metzler C, Fink C, Lamprecht P, et al. Maintenance of remission with leflunomide in Wegener’s granulomatosis. Rheumatology 2004; 63: 315–20

    Google Scholar 

  130. McMurray RW, Harisdangkul V. Mycophenolate mofetil: selective T cell inhibition. Am J Med Sci 2002; 323: 194–6

    Article  PubMed  Google Scholar 

  131. Nowack R, Göbel U, Kloosker P, et al. Mycophenolate mofetil for maintenance therapy of Wegener’s granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999; 10: 1965–71

    PubMed  CAS  Google Scholar 

  132. Haubitz M, de Groot K. Tolerance of mycophenolate mofetil in end-stage renal disease patients with ANCA-associated vasculitis. Clin Nephrol 2002; 57: 421–4

    PubMed  CAS  Google Scholar 

  133. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener’s granulomatosis. Arthritis Rheum 2004; 51: 278–83

    Article  PubMed  CAS  Google Scholar 

  134. Joy MS, Hogan SI, Jennette JC, et al. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 2005; 20: 2725–32

    Article  PubMed  CAS  Google Scholar 

  135. Stegeman CA, Cohen Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener’s granulomatosis. Ann Intern Med 1994; 20: 12–7

    Google Scholar 

  136. Reinhold-Keller E, De Groot K, Rudert H, et al. Response to trimethoprim/sulfamethoxazole in Wegener’s granulomatosis depends on the phase of disease. Q J Med 1996; 89: 15–23

    Article  CAS  Google Scholar 

  137. Stegeman CA, Cohen Tervaert JW, de Jong PE, et al. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. N Engl J Med 1996; 335: 16–20

    Article  PubMed  CAS  Google Scholar 

  138. Brown KK. Pulmonary vasculitis. Proc Am Thorac Soc 2006; 3: 48–57

    Article  PubMed  CAS  Google Scholar 

  139. Kerr GS, Fleisher TA, Hallahan CW, et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener’s granulomatosis. Arthritis Rheum 1993; 36: 365–71

    Article  PubMed  CAS  Google Scholar 

  140. Kyndt X, Reumaux D, Bridoux F, et al. Serial measurement of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 1999; 106: 527–33

    Article  PubMed  CAS  Google Scholar 

  141. Girard T, Mahr A, Noel L-H, et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener’s granulomatosis? A prospective study. Rheumatology 2001; 40: 147–51

    Article  PubMed  CAS  Google Scholar 

  142. Luqmani RA, Flossmann O. Outcome in small-vessel systemic vasculitis. J Rheumatol 2006; 33: 1224–7

    PubMed  Google Scholar 

  143. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine 1996; 75: 17–28

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Dipartimento di Clinica Medica, Nefrologia e Scienze della Prevenzione dell’Università degli Studi di Parma, Parma, Italy

    Alberto Pesci

  2. Unità Operativa di Reumatologia e Medicina Interna, Dipartimento Osteo-Articolare, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

    Paolo Manganelli

Authors
  1. Alberto Pesci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paolo Manganelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alberto Pesci.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pesci, A., Manganelli, P. Respiratory System Involvement in Antineutrophil Cytoplasmic-Associated Systemic Vasculitides. Drugs R D 8, 25–42 (2007). https://doi.org/10.2165/00126839-200708010-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200708010-00003

Keywords

Search

Navigation